Frexalimab – Results of the Phase II Study and their Significance
This is about a B-cell inhibitor called Frexalimab. It is still in the pipeline and is being tested against MS. When it comes to new therapeutic strategies for the treatment of multiple sclerosis, the influence
Continue reading